External quality assessment for molecular detection of human papillomaviruses

Journal of Clinical Virology

Volumn 48, Issue 4, 2010, Pages 251-254

  Fagan, Elizabeth J ^a   Moore, Catherine ^b   Jenkins, Claire ^a   Rossouw, Anneline ^a   Cubie, Heather A ^b   James, Vivienne L A ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

EQA; External quality assessment; HPV; Human papillomavirus

Indexed keywords

ARTICLE; CYTOLOGY; GENOTYPE; NONHUMAN; PERFORMANCE; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; VIRUS DETECTION; WART VIRUS; EVALUATION STUDY; FEMALE; GENETICS; HEALTH CARE QUALITY; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; STANDARDS; UNITED KINGDOM; VIROLOGY;

FEMALE; GREAT BRITAIN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUALITY ASSURANCE, HEALTH CARE; VIROLOGY;

EID: 77954661219     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.05.006     Document Type: Article

References (26)

1. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009, 10:321-322.
2. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
3. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008, 110:S18-25.
4. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009, 199:919-922.
5. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
6. Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005, 32(Suppl. 1):S43-51.
7. Albrecht V., Chevallier A., Magnone V., Barbry P., Vandenbos F., Bongain A., et al. Easy and fast detection and genotyping of high-risk human papillomavirus by dedicated DNA microarrays. J Virol Methods 2006, 137:236-244.
8. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
9. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
10. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
11. Ronco G., Arbyn M., Segnan N. Cervical screening according to age and HPV status. BMJ 2009, 339:b3005.
12. European Centre for Disease Prevention and Control Guidance for the introduction of HPV vaccines in EU countries 2008, European Centre for Disease Prevention and Control, Stockholm.
13. Carozzi F., Bisanzi S., Sani C., Zappa M., Cecchini S., Ciatto S. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007, 45:364-369.
14. Sandri M.T., Lentati P., Benini E., Dell'Orto P., Zorzino L., Carozzi F.M. Comparison of the Digene HC2 assay and the roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 2006, 44:2141-2146.
15. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17:3033-3042.
16. Dalstein V., Merlin S., Bali C., Saunier M., Dachez R., Ronsin C. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods 2009, 156:77-83.
17. Sabol I., Salakova M., Smahelova J., Pawlita M., Schmitt M., Gasperov N.M. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 2008, 46:1606-1613.
18. Stevens M.P., Garland S.M., Tabrizi S.N. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008, 147:290-296.
19. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
20. Cubie H.A., Moore C., Waller M., Moss S. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. J Clin Virol 2005, 33:287-292.
21. Castle P.E., Schiffman M., Burk R.D., Wacholder S., Hildesheim A., Herrero R., et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002, 11:1394-1399.
22. Peyton C.L., Schiffman M., Lorincz A.T., Hunt W.C., Mielzynska I., Bratti C. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998, 36:3248-3254.
23. Castle P.E., Wheeler C.M., Solomon D., Schiffman M., Peyton C.L. Interlaboratory reliability of hybrid capture 2. Am J Clin Pathol 2004, 122:238-245.
24. Kornegay J.R., Roger M., Davies P.O., Shepard A.P., Guerrero N.A., Lloveras B. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol 2003, 41:1080-1086.
25. Dunn S.T., Allen R.A., Wang S., Walker J., Schiffman M. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J Virol Methods 2007, 143:45-54.
26. Wilkinson D.E., Baylis S.A., Padley D., Heath A.B., Ferguson M., Pagliusi S.R., et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010, 126:2969-2983.